New drug duo aims to shrink lung tumors before surgery
NCT ID NCT07281209
Summary
This study is testing whether a combination of two drugs, SHR-A1811 and adebelimumab, can shrink tumors before surgery in people with early-stage, operable lung cancer that has a specific genetic change called HER2. The goal is to see if this pre-surgery treatment helps remove more of the cancer and lowers the chance of it coming back. About 40 participants will receive the drug combination and then have surgery.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NSCLC are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.